News Scan for Dec 17, 2018

More acute flaccid myelitis cases
;
Romaine grower produce recall
;
US flu vaccine uptake
;
Quadrivalent flu vaccine in kids
;
Mumps in Australia

With 7 more AFM cases, US outbreak grows to 165 cases in 36 states

The US Centers for Disease Control and Prevention (CDC) recorded 7 new confirmed cases of acute flaccid myelitis (AFM) this past week, bringing 2018's total to 165 confirmed cases.

According to the CDC, the 165 cases are among the total of 320 reports that it received regarding patients under investigation). CDC and local health departments are still investigating some of those suspected cases.

For the third week in a row, Texas reported new cases and now has 24 confirmed cases, the most of any state. Colorado has 15, Ohio 12, and New Jersey 10. Thirty-two other states report at least 1 case of the rare, polio-like illness. 2018 has seen the most AFM cases of any outbreak year since 2014, when the CDC began tracking the condition. Since the AFM has clustered every 2 years in the United States.

AFM typically affects the gray matter surrounding the spinal cord and leads to muscle weakness in pediatric patients. In 90% of patents, symptoms develop following a mild respiratory illness.
Dec 17 CDC
update

 

Farm linked to romaine E coli outbreak recalls additional produce

Adam Brothers Farming, Inc., the California farm recently identified as a likely source of Escherichia coli O157:H7 outbreak linked to romaine lettuce, has also recalled its red leaf lettuce, green leaf lettuce, and cauliflower, though no illnesses have been connected to those products.

In a Dec 13 press release, the company said the recalled products were harvested from Nov 27 to Nov 30 on particular fields and that it was taking the step out of an abundance of caution.

The cauliflower was distributed to 10 states, Mexico, and Canada. Both types of lettuce were distributed to six states and Canada. And red leaf lettuce was distributed to a wholesaler in Minnesota and in Mexico.

The company said the produce may have come in contact with filtered, treated water that came from a reservoir from which a sediment sample tested positive for E coli. It added that the filtered, treated water was negative for E coli.
Dec 13 Adam Bros press release

 

Early CDC estimate shows increase in flu vaccine uptake

A survey that the CDC uses to track flu vaccination suggests that, as of the middle of November, immunization levels are running ahead of last season at this time.

In a Dec 14 FluVaxView update, the CDC said the National Immunization Survey-Flu shows that coverage in children is at 45.6%, reflecting an increase of 6.8 percentage points compared with this time last season, mainly owing to increased uptake in kids ages 12 and younger. Coverage for adults is at 44.9%, up 6.4 percentage points from this point last season.

The child and teen estimates are based on a random cell-phone surveys. Interviews were conducted from Oct 1 to Nov 17 and included 24,083 children for whom the parent reported a vaccination status. The adult portion of the estimate is based on an Internet panel survey that was conducted during the first half of November. It includes data from 4,286 respondents who answered the flu vaccination question.

As of Nov 30, vaccine makers had distributed 163.8 million doses, up from 155 million for all of last season.

The CDC said flu vaccination is the best way to prevent deaths and hospitalization from flu and that people not yet immunized should get vaccinated as soon as possible.
Dec 14 FluVaxView update

 

Quadrivalent flu shot shown 51% effective in young children

Two doses of an inactivated quadrivalent influenza vaccine made by Sanofi (Vaxigrip Tetra) was effective in young children, even against mismatched strains, according to a study in both Northern and Southern Hemisphere children that spanned four flu seasons, two in each hemisphere. An international research team led by Sanofi reported its findings on Dec 14 in Vaccine.

Healthy children ages 6 to 35 months who had not previously been vaccinated against flu received two full doses of Vaxigrip Tetra 28 days apart, placebo, or an investigational trivalent inactivated vaccine that contained an influenza B strain from an alternate lineage. The trial was conducted in Latin America, Asia, Africa, and Europe during the Northern Hemisphere's 2014-15 and 2015-16 flu seasons and the Southern Hemisphere's 2014 and 2015 flu seasons.

The efficacy analysis included 4,980 children who completed the study protocol. Vaccine efficacy for Vaxigrip Tetra against any influenza A or B strain for was 51.0% (97% confidence interval [CI], 37.36% to 61.86%) and was 68.4% (97% CI, 47.07% to 81.92%) against vaccine-matched strains. The authors noted that only about one quarter of confirmed flu infections involved vaccine-similar strains.

Safety patterns were similar for Vaxigrip Tetra, placebo, and the investigational vaccine, though injection-site reactions were slightly more common for Vaxigrip Tetra than placebo.

The team said the findings are similar to reports for another full-dose inactivated quadrivalent vaccine in the same age-group. "Together, the results provide convincing evidence that inactivated quadrivalent influenza vaccines are effective at preventing influenza in children aged 6–35 months," they concluded.
Dec 14 Vaccine study

 

Study: More mumps in Australia despite high vaccination coverage

Even among communities with high vaccination coverage rates, a protracted mumps outbreak grew in size and frequency in Western Australia in 2015 and 2016, according to a new study published in The Lancet Infectious Diseases.

The population-based surveillance study looked at mumps cases reported in 2015 and 2016 in the Western Australia Infectious Diseases Database, and compared the case information with data from the Australian Childhood Immunization Register.

Aboriginal people accounted for most of the case-patients in the outbreak, representing 798 of 893 cases (89%). "The risk for Aboriginal Australians to acquire mumps was 37 times higher than the risk for non-Aboriginal Australians living in the same areas, despite high vaccination coverage in both groups," the authors said.

Patients ages 15 to 19 years were most likely to be diagnosed as having mumps, despite a high vaccination rate among them. Of the 419 patients in the study between the ages of 1 and 19, 89% were fully vaccinated with two doses of measles, mumps, and rubella (MMR) vaccine, and 7% had at least one dose.

The study authors said their findings suggest the need for a third additional dose of MMR vaccine among some populations, adding that Aboriginals may be more prone to mumps because of  waning immunity, immune escape, large household size with suboptimal hygiene, and high levels of mobility and social interaction.

In an accompanying commentary, Helen S. Marshall, MD and Stanley Plotkin, MD, write that waning immunity was the likely cause of these outbreaks. Unlike measles and rubella, mumps continues to flare in highly vaccinated populations, and literature shows that as many as 25% of vaccine recipients have waning immunity to mumps after receiving the vaccine. The experts warn that a third dose of MMR may not be feasible or economical in most outbreak settings.
Dec 14 Lancet Infect Dis
study
Dec 14 Lancet Infect Dis
commentary

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»